PedAM
Pediatric Disease Annotations & Medicines
| Disease | vascular disease |
| Phenotype | |diabetes |
| Sentences | 529 |
| PubMedID- 26177892 | [59]n = 669inclusion: uncontrolled stage i–ii htn (dbp 90–109 mmhg), background treatment with 1 or 2 anti-htn meds (acei, arb, or diuretic)exclusion: secondary/malignant htn, bradycardia, bmi >35 kg/m2, contraindication to bbs, uncontrolled diabetes, history of mi or cerebrovascular disease, hf, afib or recurrent tachyarrhythmia, severe renal/hepatic diseaserct, db, pbo-controlledneb: 5, 10, or 20 mg/day added to ongoing therapypbo added to ongoing therapyfollow-up at 12 weeksprimary: change in sitting dbpsecondary: change in sitting sbp, response rate (dbp <90 mmhg or decrease in dbp ≥10 mmhg), percent achieving treatment goal (<140/90 mmhg), adverse eventsdbp (ls mean change ± se, mmhg)neb: 5/10/20: −6.6 ± 1.0, −6.8 ± 1.0, −7.9 ± 1.1 (all p < 0.001 vs pbo)pbo: −3.3 ± 1.04sbp (ls mean change ± se, mmhg)neb: 5/10/20: −5.7 ± 1.7 (p < 0.001), −3.7 ± 1.7 (p = 0.015), −6.3 ± 1.7 (p < 0.001)pbo: −0.1 ± 1.7response rate (%)neb: 53.0 (p = 0.028), 60.1 (p = 0.001), 65.1 (p < 0.001)pbo: 41.3bp control (%)neb: 43.2, 41.3, 52.7 (all p ≤ 0.029)pbo: 29.3aes (%)neb (combined doses), 40.2pbo, 38.9 weber et al. |
| PubMedID- 26120352 | We believe that our findings will provide fundamental insights for the prevention and treatment of cardiovascular diseases in patients with diabetes and hhcy. |
| PubMedID- 25532311 | [c-peptide level as an early diagnostic marker of metabolic syndrome and predictor of cardiovascular disease in patients with diabetes mellitus type 2]. |
| PubMedID- 24187621 | Risk of cardiovascular diseases in diabetes mellitus and serum concentration of asymmetrical dimethylarginine. |
| PubMedID- 21108545 | Gestational diabetes mellitus and risk of future maternal cardiovascular disease. |
| PubMedID- 22848415 | Adjusted for age, indication, diabetes, history of cardiovascular disease, socio economic position, and >90 sick-leave days in total the year prior to cabg. |
| PubMedID- 26178521 | Obesity is a well-known risk factor for several chronic illnesses including type ii diabetes, hypertension and scores of cardiovascular diseases. |
| PubMedID- 24094079 | The risk of cardiovascular disease in diabetes mellitus is pushed sharply higher by hypercholesterolemia, especially elevated low-density lipoprotein cholesterol (ldl-c). |
| PubMedID- 24432038 | Aggressive treatment of dyslipidemia will reduce the risk of cardiovascular disease in patients with diabetes mellitus. |
| PubMedID- 25217178 | Background: the role of statins in the development of microvascular disease in patients with diabetes is unknown. |
| PubMedID- 23913590 | Pediatric cancer survivors have increased risk of obesity, hypertension, dyslipidemia, and type 2 diabetes, leading to premature cardiovascular disease (cvd). |
| PubMedID- 26180307 | Theage-adjusted incidence of hypertension and coronary heart disease was 38% and 24%,respectively, showing a clear incidence of diabetes associated with cardiovascular diseasein saudi arabia. |
| PubMedID- 20513290 | Conclusion: cardiovascular and cerebrovascular diseases, together with diabetes were the fastest increasing ones over the past 10 years and becoming the major diseases, making the xinjiang production and construction corps an aging population. |
| PubMedID- 21647437 | Model b: model a additionally adjusted for education level, smoking status, alcohol consumption, medication for hypertension, medication for dyslipidaemia, medication for depression, baseline diabetes status, family history of cardiovascular disease and sleep duration. |
| PubMedID- 22447230 | This manuscript presents an overview of the biology of the haptoglobin genotype and reviews the literature concerning its role in the development of cardiovascular disease among individuals with diabetes mellitus. |
| PubMedID- 21749443 | Waist circumference and metabolic risk factors have separate and additive effects on the risk of future type 2 diabetes in patients with vascular diseases. |
| PubMedID- 22427765 | In patients with diabetes, the risk of vascular disease is increased by advanced age, smoking, hypertension, lipid metabolism disturbances, diabetes duration, and the presence of peripheral neuropathy [6-11]. |
| PubMedID- 23577222 | Postprandial hyperglycemia may be a risk factor for cardiovascular disease in individuals with diabetes [6]. |
| PubMedID- 21447669 | As the results of the heart2d trial suggest that glucose variability is not a risk factor for cardiovascular diseases in patients with type 2 diabetes treated with insulin (1,2), several “burning” questions can be raised, why could glucose variability be a risk factor for cardiovascular diseases in patients with type 2 diabetes who are treated with oral hypoglycemic agents alone, but not in those who are treated with insulin, and does insulin per se neutralize the deleterious effects of glycemic variability on oxidative stress in patients treated with it? |
| PubMedID- 24406095 | However, the early treatment diabetic retinopathy study report 14 results from 1992 support treatment with asa in patients with diabetes at increased risk of cardiovascular disease and found no increased risk of retinal bleeding associated with the use [6]. |
| PubMedID- 22322078 | To date, the drug approach to prevention of microvascular disease starting with pre-diabetes has not been evaluated. |
| PubMedID- 20825660 | Similarly, obesity and being overweight are risk factors for diseases such as type 2 diabetes, certain types of cancer and cardiovascular diseases, and affect between 30% and 80% of adults and up to one third of children [4]. |
| PubMedID- 24624891 | Distribution of cardiovascular disease and retinopathy in patients with type 2 diabetes according to different classification systems for chronic kidney disease: a cross-sectional analysis of the renal insufficiency and cardiovascular events (riace) italian multicenter study. |
| PubMedID- 20530022 | Management of diabetes mellitus in patients with cardiovascular disease in the bypass angioplasty revascularization investigation 2 diabetes (bari 2d) trial. |
| PubMedID- 25018969 | Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the american heart association and the american diabetes association. |
| PubMedID- 22115901 | Observational studies suggest an association between the extent of hyperglycaemia and the risk of death and of macrovascular and microvascular disease in patients with type 2 diabetes.1 2 3 three recent randomised clinical trials in patients with type 2 diabetes were not able to detect (or reject the possibility of) reduced cardiovascular disease or mortality with intensive compared with conventional glycaemic control.4 5 6 worries arose as the results from the action to control cardiovascular risk in diabetes (accord) trial in 2008 showed increased all cause mortality and cardiovascular mortality in the intensive treatment group compared with conventional treatment.4 the increased mortality led to early termination of the accord trial.4 on the other hand, randomised clinical trials have indicated a beneficial effect on microvascular complications of intensive versus conventional glycaemic control in patients with type 2 diabetes. |
| PubMedID- 21330642 | Objective: pulse pressure (pp), an estimate of arterial stiffness, has been shown to be associated with incident cardiovascular disease (cvd) in patients with type 1 diabetes (t1d). |
| PubMedID- 22301118 | Although identification can be useful, there are no studies showing that screening alone improves depressive symptoms and cardiac outcomes (37) or diabetes outcomes (38) in patients with cardiovascular disease or diabetes, respectively. |
| PubMedID- 26219736 | Albuminuria is a strong predictor of cardiovascular disease, especially in patients with diabetes and hypertension (brantsma et al., 2006; de jong & curhan, 2006). |
| PubMedID- 23349538 | This has implications for atherogenesis and vascular disease in diabetes and insulin-resistant states. |
| PubMedID- 24582090 | Cardiovascular disease in diabetes mellitus: risk factors and medical therapy. |
| PubMedID- 21929289 | Background: the mechanisms responsible for the accelerated cardiovascular disease in diabetes, as well as the increased hypertrophic effects of angiotensin ii (ang ii) under hyperglycemic condition, are not very clear. |
| PubMedID- PMC4033993 | However, use of aspirin in primary prevention of cardiovascular disease, or in patients with diabetes mellitus, or in those with peripheral vascular disease is not supported by the current evidence. |
| PubMedID- 21257100 | Primary and secondary prevention strategy for cardiovascular disease in diabetes mellitus. |
| PubMedID- 22496883 | This study provides new targets for drug development and new strategies for the prevention and treatment of vascular diseases in diabetes patients with hypertension. |
| PubMedID- 22536510 | Subjects with diabetes and clinical evidence of cardiovascular diseases or receiving antacids, lipid-lowering drugs, or antioxidant supplements were excluded from the study to avoid possible interferences on pon1 activity and plasma lipids. |
| PubMedID- 26116592 | Plasma adiponectin levels inversely correlate to clinical parameters in type 2 diabetes mellitus patients with macrovascular diseases. |
| PubMedID- 20977287 | However, although antiplatelet therapy with low-dose aspirin has been reported to prevent vascular events in high-risk patients with cardiovascular disease, recent studies in patients with pad or diabetes mellitus have failed to support the efficacy of aspirin in preventing vascular events in these patient populations. |
| PubMedID- 22305579 | Conclusions: time-dependent variation of fpg was a strong predictor of all-cause, expanded, and nonexpanded cardiovascular disease-related mortality in patients with type 2 diabetes, suggesting that glucose variation may become a measure in clinical practice for the goal in the management of these patients. |
| PubMedID- 26557879 | Although aspirin has been in clinical use for more than a century, there is still much to be learned about its future uses, particularly in cancer and in patients who are at particularly high risk of cardio- and cerebrovascular diseases—such as those with diabetes mellitus and long-term survivors of hiv infection. |
| PubMedID- 25905182 | Metformin and perhaps pioglitazone decrease cardiovascular disease in patients with type 2 diabetes to a greater extent than other treatment modalities. |
| PubMedID- 24167560 | Hazard ratios were calculated after adjustment for age, sex, diabetes mellitus, previous history of cardiovascular disease, smoking status, systolic blood pressure, the use of lipid-lowering therapy, bmi, and biochemical data (hemoglobin, albumin, ca×p products, and log hs-crp levels). |
| PubMedID- 24499591 | Even though the between-group differences in crp in the present study were small, and crp has been used as a consistent marker for evaluating the extent of cardiovascular diseases in subjects with type 1 diabetes [66-70], we suggest that others determinants, such as genetic predisposition, coping mechanisms, and environmental factors, make individuals more susceptible to changes in this inflammatory marker. |
| PubMedID- 26239558 | This is consistent with the observation that most guidelines recommend more intense screening, especially for cardiovascular disease, in patients with diabetes [28]. |
| PubMedID- 23715623 | Although insulin injections can provide good glycemic control, many patients with type 1 diabetes still have complications of hyperglycemia, including cardiovascular disease, retinopathy, and neuropathy. |
| PubMedID- 26491340 | Background: hypertension is a highly prevalent risk factor for cardiovascular disease in patients with type 1 diabetes mellitus. |
| PubMedID- 21080740 | There was a beneficial effect of intensive glucose control on cardiovascular disease in patients with type 1 diabetes in only one trial. |
| PubMedID- 24688629 | In fact, it may be that this rapid aging of apoa-1, a key protein in lipoprotein metabolism, causes a higher risk of macrovascular disease in persons with type 1 diabetes [22]. |
| PubMedID- 23275224 | While cardiovascular diseases in diabetes are macrovascular in origin, retinopathy is microvascular, and each has distinct and different set of major etiological factors. |
| PubMedID- 24672797 | The pathophysiology of vascular disease in diabetes involves abnormalities in endothelial, vascular smooth muscle cell and platelet function. |